Joseph Capper Buys 50,000 Shares of TELA Bio (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) Director Joseph Capper purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was bought at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the completion of the transaction, the director owned 104,827 shares in the company, valued at approximately $111,116.62. This represents a 91.20% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

TELA Bio Stock Performance

TELA Bio stock opened at $1.29 on Friday. TELA Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.69. The company has a quick ratio of 2.38, a current ratio of 2.99 and a debt-to-equity ratio of 8.82. The company has a market capitalization of $58.23 million, a P/E ratio of -1.68 and a beta of 1.36. The stock’s 50 day moving average is $0.79 and its 200 day moving average is $0.79.

TELA Bio (NASDAQ:TELA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The company had revenue of $19.29 million for the quarter, compared to analysts’ expectations of $20.01 million. On average, equities research analysts predict that TELA Bio, Inc. will post -0.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TELA Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. UP Strategic Wealth Investment Advisors LLC bought a new stake in shares of TELA Bio in the second quarter worth approximately $91,000. BlackRock Inc. purchased a new position in shares of TELA Bio during the second quarter valued at approximately $281,000. WealthTrust Axiom LLC lifted its position in TELA Bio by 39.1% during the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock valued at $381,000 after purchasing an additional 90,650 shares during the period. Perkins Capital Management Inc. lifted its position in TELA Bio by 1.5% during the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock valued at $879,000 after purchasing an additional 20,910 shares during the period. Finally, Stonepine Capital Management LLC purchased a new stake in TELA Bio in the second quarter worth approximately $1,996,820. Institutional investors own 94.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, TELA Bio currently has a consensus rating of “Hold” and an average price target of $2.20.

TELA Bio Company Profile

TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.

The company’s principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.